Advanced MR imaging techniques in the evaluation of nonenhancing gliomas: Perfusion-weighted imaging compared with proton magnetic resonance spectroscopy and tumor grade

Neuroradiology Journal

Volumn 26, Issue 5, 2013, Pages 531-541

  Sahin, Neslin ^a,b   Melhem, Elias R ^b,c   Wang, Sumei ^b   Krejza, Jaroslaw ^b,c   Poptani, Harish ^b   Chawla, Sanjeev ^b   Verma, Gaurav ^b  

^a SIFA UNIVERSITY   (Turkey)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

MR spectroscopy; Nonenhancing glioma; Perfusion MRI

Indexed keywords

CREATININE; GADODIAMIDE; GADOLINIUM PENTETATE MEGLUMINE; INOSITOL;

ADULT; AGE; ARTICLE; ASTROCYTOMA; CANCER PATIENT; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; EVALUATION; FEMALE; FRONTAL LOBE; GLIOBLASTOMA; GLIOMA; HUMAN; INTERMETHOD COMPARISON; MALE; NONENHANCING GLIOMA; NUCLEAR MAGNETIC RESONANCE SCANNER; OLIGODENDROGLIOMA; PERFUSION WEIGHTED IMAGING; PONS; PROTON NUCLEAR MAGNETIC RESONANCE; SENSITIVITY AND SPECIFICITY; SEX; TEMPORAL LOBE; TUMOR GROWTH; TUMOR VOLUME;

EID: 84888771620     PISSN: 19714009     EISSN: None     Source Type: Journal    
DOI: 10.1177/197140091302600506     Document Type: Article

References (26)

1. Kleihues P, Cavenee WK. Pathology and genetics of tumours of the nervous system. Lyon: International Agency for Research on Cancer; 2000.
2. Morita N, Wang S, Chawla S, et al. Dynamic susceptibility contrast perfusion weighted imaging in grading of nonenhancing astrocytomas. J Magn Reson Imaging. 2010; 32 (4): 803-808.
3. Ginsberg LE, Fuller GN, Hashmi M, et al. The significance of lack of MR contrast enhancement of supratentorial brain tumors in adults: histopathological evaluation of a series. Surg Neurol. 1998; 49 (4): 436-440. (Pubitemid 28153024)
4. Al-Okaili RN, Krejza J, Wang S, et al. Advanced MR imaging techniques in the diagnosis of intraaxial brain tumors in adults. Radiographics. 2006; 26 (Suppl 1): S173-189.
5. Maia AC Jr, Malheiros SM, da Rocha AJ, et al. MR cerebral blood volume maps correlated with vascular endothelial growth factor expression and tumor grade in nonenhancing gliomas. Am J Neuroradiol. 2005; 26 (4): 777-783. (Pubitemid 43079767)
6. Batra A, Tripathi RP, Singh AK. Perfusion magnetic resonance imaging and magnetic resonance spectroscopy of cerebral gliomas showing imperceptible contrast enhancement on conventional magnetic resonance imaging. Australas Radiol. 2004; 48 (3): 324-332. (Pubitemid 39421075)
7. Cha S, Knopp EA, Johnson G, et al. Intracranial mass lesions: dynamic contrast-enhanced susceptibilityweighted echo-planar perfusion MR imaging. Radiology. 2002; 223 (1): 11-29.
8. Rorden C, Brett M. Stereotaxic display of brain lesions. Behav Neurol. 2000; 12 (4): 191-200. (Pubitemid 32843166)
9. Wetzel SG, Cha S, Johnson G, et al. Relative cerebral blood volume measurements in intracranial mass lesions: interobserver and intraobserver reproducibility study. Radiology. 2002; 224 (3): 797-803. (Pubitemid 34919816)
10. Govindaraju V, Young K, Maudsley AA. Proton NMR chemical shifts and coupling constants for brain metabolites. NMR Biomed. 2000; 13 (3): 129-153. (Pubitemid 30414704)
11. Lev MH, Ozsunar Y, Henson JW, et al. Glial tumor grading and outcome prediction using dynamic spinecho MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas. Am J Neuroradiol. 2004; 25 (2): 214-221. (Pubitemid 38235298)
12. McKnight TR, Smith KJ, Chu PW, et al. Choline metabolism, proliferation, and angiogenesis in nonenhancing grades 2 and 3 astrocytoma. J Magn Reson Imaging. 2011; 33 (4): 808-816.
13. Liu X, Tian W, Kolar B, et al. MR diffusion tensor and perfusion-weighted imaging in preoperative grading of supratentorial nonenhancing gliomas. Neuro Oncol. 2011; 13 (4): 447-455.
14. Law M, Yang S, Wang H, et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. Am J Neuroradiol. 2003; 24 (10): 1989-1998. (Pubitemid 37444849)
15. Castillo M, Kwock L. Proton MR spectroscopy of common brain tumors. Neuroimaging Clin N Am. 1998; 8 (4): 733-752. (Pubitemid 28532515)
16. Fayed N, Modrego PJ. The contribution of magnetic resonance spectroscopy and echoplanar perfusion-weighted MRI in the initial assessment of brain tumors. J Neurooncol. 2005; 72 (3): 261-265. (Pubitemid 40867410)
17. Toyooka M, Kimura H, Uematsu H, et al. Tissue characterization of glioma by proton magnetic resonance spectroscopy and perfusion-weighted magnetic resonance imaging: glioma grading and histological correlation. Clin Imaging. 2008; 32 (4): 251-258. (Pubitemid 351899273)
18. Cerdan S, Parrilla R, Santoro J, et al. 1H NMR detection of cerebral myo-inositol. FEBS Lett. 1985; 187 (1): 167-172.
19. Danielsen ER, Ross B. Magnetic resonance spectroscopy diagnosis of neurological diseases. New York: Marcel Decker; 1999. p 30-34.
20. Castillo M, Smith JK, Kwock L. Correlation of myoinositol levels and grading of cerebral astrocytomas. Am J Neuroradiol. 2000; 21 (9): 1645-1649.
21. Law M, Oh S, Babb JS, et al. Low-grade gliomas: dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging - Prediction of patient clinical response. Radiology. 2006; 238 (2): 658-667. (Pubitemid 43134379)
22. Danchaivijitr N, Waldman AD, Tozer DJ, et al. Low-grade gliomas: do changes in rCBV measurements at longitudinal perfusion-weighted MR imaging predict malignant transformation? Radiology. 2008; 247 (1): 170-178.
23. Law M, Oh S, Johnson G, et al. Perfusion magnetic resonance imaging predicts patient outcome as an adjunct to histopathology: a second reference standard in the surgical and nonsurgical treatment of low-grade gliomas. Neurosurgery. 2006; 58 (6): 1099-1107. (Pubitemid 43879544)
24. Guillevin R, Menuel C, Abud L, et al. Proton MR spectroscopy in predicting the increase of perfusion MR imaging for WHO grade II gliomas. J Magn Reson Imaging. 2012; 35 (3): 543-550.
25. Xu M, See SJ, Ng WH, et al. Comparison of magnetic resonance spectroscopy and perfusion-weighted imaging in presurgical grading of oligodendroglial tumors. Neurosurgery. 2005; 56 (5): 919-926.
26. Chawla S, Oleaga L, Wang S, et al. Role of proton magnetic resonance spectroscopy in differentiating oligodendrogliomas from astrocytomas. J Neuroimaging. 2010; 20 (1): 3-8.